CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
19 hedge funds and large institutions have $883K invested in CASI Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.79% less ownership
Funds ownership: 3.38% → 2.59% (-0.79%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
97% less capital inflows, than outflows
Capital inflows: $7.49K | Capital outflows: $258K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$6.39K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$777 |
| 3 |
Tower Research Capital (TRC)
New York
|
+$291 |
| 4 |
KA
Kozak & Associates
Highlands Ranch,
Colorado
|
+$24 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$116K |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
-$59.2K |
| 3 |
WSC
Wellington Shields & Co
New York
|
-$28.5K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$25.8K |
| 5 |
Jane Street
New York
|
-$14.3K |
CASI Hedge Fund Activity: Q3 2023 in Review
19 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2023, worth a combined $883K — down 22% from $1.12M a quarter earlier.
Fund positioning in CASI was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $6.39K. The largest seller was Vanguard Group, cutting an estimated $116K.
- 19 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $883K of CASI Pharmaceuticals stock for Q3 2023, down 22% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2023 was Renaissance Technologies, an estimated $6.39K added.
- The largest CASI Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2023.